AZNAstraZenecaSigning up patients
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 630 (planned)
- Started
- Apr 14, 2022
- Main results expected
- May 28, 2030
- Fully finished
- May 28, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with pathological complete response (pCR)
Measured over: From randomization to approximately 15 weeks after the first dose of study interventions
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Measured over: Until Day 90 after the last dose of study interventions (Up to approximately 3 years)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05061550 · record last updated 2026-10-21 · checked 2026-11-09 15:47 UTC